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Abstract: The administration of lithium–pilocarpine (LiPilo) in adult rats is a validated model
reproducing the main clinical and neuropathological features of temporal lobe epilepsy (TLE).
Previous studies have shown that carisbamate (CRS) has the property of modifying epileptogenesis
in this model. When treated with CRS, about 50% of rats undergoing LiPilo status epilepticus
(SE) develop non-convulsive seizures (NCS) instead of convulsive ones (commonly observed in
TLE). The goal of this work was to determine some of the early changes that occur after CRS
administration, as they could be involved in the insult- and epileptogenesis-modifying effects of
CRS. Thus, we performed high-performance liquid chromatography (HPLC) to quantify levels of
amino acids and monoamines, and c-Fos immunohistochemical labeling to map cerebral activation
during seizures. Comparing rats treated one hour after SE onset with saline (CT), CRS, or diazepam
(DZP), HPLC showed that 4 h after SE onset, dopamine (DA), norepinephrine (NE), and GABA
levels were normal, whereas serotonin levels were increased. Using c-Fos labeling, we demonstrated
increased activity in thalamic mediodorsal (MD) and laterodorsal (LD) nuclei in rats treated with
CRS. In summary, at early times, CRS seems to modulate excitability by acting on some monoamine
levels and increasing activity of MD and LD thalamic nuclei, suggesting a possible involvement of
these nuclei in insult- and/or epileptogenesis-modifying effects of CRS.
Keywords: carisbamate 1; temporal-lobe epilepsy 2; brain activity 3
1. Introduction
Temporal lobe epilepsy (TLE) is characterized by recurrent spontaneous convulsive seizures [1]
that are associated with significant neuronal loss and morphological alterations affecting mainly mesial
temporal structures such as the hippocampal formation and amygdala [1–3]. The pilocarpine-induced
epilepsy model reproduces the main clinical and pathophysiological features of human TLE, i.e.,
hippocampal sclerosis, cell dispersion in the dentate gyrus, mossy fiber sprouting, and gliosis [4,5].
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In this model, an initial phase of status epilepticus (SE) is followed by a latent period lasting 7–44 days,
leading to the occurrence of spontaneous recurrent motor seizures [4]. In addition, this model also
reproduces significant neuronal damage in the mesial structures of the brain [6].
Despite numerous commercially available antiepileptic drugs, approximately 20–30% of patients
with TLE present refractory seizures [7]. Experimental studies have shown that a new drug,
carisbamate (CRS, RWJ-333369; S-2-O-carbamoyl-1-o-chlorophenyl-ethanol) possesses the property of
modifying epileptogenesis in the TLE model induced by lithium–pilocarpine (LiPilo) [8–10]. When
injected at one hour after SE onset in rats, CRS induces widespread neuroprotection and alters the
development of TLE in approximately 50% of the rats, leading to non-convulsive absence-like seizures
(NCS) instead of the complex partial seizures of the LiPilo model [10]. In these animals, NCS are
characterized by behavioral arrest accompanied by bilateral synchronous SWDs [11,12]. Interestingly,
most rats treated with CRS that later develop NCS show a reduction of epileptiform events during SE
at 2–3 h after CRS administration, i.e., at 4–5 h after SE onset [10].
Previous studies have shown that CRS may modulate neuronal excitability by inhibiting
voltage-gated sodium channels, thereby reducing action potential discharges [13]. In addition,
CRS reduces glutamatergic transmission by inhibiting AMPA and NMDA excitatory post-synaptic
potentials [14]. More recently, it was reported that CRS increases the tonic activation of somatodendritic
5-HT1A serotonergic receptors, leading to the inhibition of pyramidal neurons in the hippocampus.
Moreover, CRS modulates noradrenergic and dopaminergic systems [15]. Some of the mechanisms
modulated by CRS are illustrated in Figure 1.
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Based on previous studies, we can hypothesize that CRS reduces neuronal excitability by acting
synergistically on several neurotransmitter systems and pathways. Supporting these data, we recently
reported [16] that CRS-NCS rats display alterations in proteins related to cellular respiration and
energy production processes, which may also impact on neuronal excitability. Among altered proteins
we observed a reduction of alpha-synuclein in rats treated with CRS and an increase of the same
protein in CRS-treated animals displaying NCS instead of convulsive seizures [16]. A recent hypothesis
suggests that epigenetic alterations in some proteins such as alpha-synuclein may be associated with
the formation of new ion channels that may disrupt membrane conductance and underlie the change
in epilepsy type induced by CRS treatment [17].
In the present study, we were interested in verifying whether the epilepsy-modifying effect of
CRS could be related to early changes in the amino acid and monoamine neurotransmission balance,
and whether CRS could act on brain regions related to seizure spread and control. We expected
to identify potential molecular mechanisms underlying the decrease in convulsive activity, which
later results in neuroprotection [10]. We chose to more specifically study hippocampus and
parahippocampal cortices since they are key structures in TLE, as well as the thalamus, which is
involved in both TLE and absence seizures [12,18]. The studies were performed at 4 h after SE onset, i.e.,
when a reduction of epileptiform events has been observed [10]. With this study, we aimed at improving
our knowledge on the early functional changes underlying the disease and epileptogenesis-modifying
effects of CRS.
2. Results
2.1. Monoamine and Amino Acid Quantification
Hippocampus: The concentrations of monoamines and amino acids in the hippocampus of rats
from control (CT), diazepam (DZP), and CRS groups are shown in Table 1, Figure 2, and Supplementary
Figures S2–S4. Our results point to a significant increase in the levels of GABA and glutamine (GLN)
in the DZP group as compared to CT rats (Figure 2A,C). The GLN level was increased in the CRS
group compared to the CT group, and the aspartate (ASP) level was increased in CRS compared to
DZP rats (Figure 2B,C).
Regarding monoamines, norepinephrine (NE) levels in the hippocampus were reduced in DZP
compared to CT and CRS rats (Figure 2F), dopamine (DA) levels were increased in DZP compared to
CT rats (Figure 2D), and serotonin (5-HT) levels were increased in the CRS compared to CT and DZP
groups (Figure 2E). The utilization rate of NE (vanilmandelic acid, (VMA)/NE) was increased in DZP
compared to CT and CRS groups (Figure 2G), while the utilization rate of DA (3,4-hydroxyphenylacetic
acid (DOPAC)/DA) and 5-HT (5-hydroxyindoleacetic acid (5HIAA)/serotonin (5HT)) was unchanged.
Thalamus: As shown in Table 1, the level of GLN in DZP and CRS rats was increased as compared
to CT rats (Figure 2I). There was also an increase of ASP in CRS compared to DZP rats (Figure 2H).
The level of NE was reduced in DZP and CRS in comparison to CT rats (Figure 2J), but no difference
was found in the level of DA and 5-HT. The utilization rates of NE and 5-HT were increased in DZP
compared to CT and CRS rats (Figure 2K,L), while the utilization rate of DA was unchanged.
Piriform cortex: As summarized in Table 1, there was no intergroup difference regarding the
level of amino acids. On the other hand, the level of NE was reduced in DZP and CRS in comparison
to CT rats (Figure 2N), while no difference in the level of DA was observed. The level of 5-HT
was significantly increased in CRS compared to CT and DZP groups (Figure 2O). Furthermore, NE
utilization rate was increased in DZP and CRS compared to CT rats (Figure 2N), while the utilization
rate of DA and 5HT (Figure 2P) was greatly reduced in CRS compared to CT and DZP groups
(Figure 2Q).
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Table 1. Effect of status epilepticus (SE) and CRS treatment on the monoamine and amino acid levels in the hippocampus, thalamus, and piriform cortex.
Hippocampus Thalamus Piriform Cortex
CT DZP CRS ANOVA BS CT DZP CRS ANOVA BS CT DZP CRS ANOVA BS
M
on
oa
m
in
es
(n
g/
g)
NE 0.39 0.12 * 0.28 #
F(2,15) = 20.73; p
< 0.001 p < 0.001 0.71 0.33 * 0.51 *
F(2,15) = 19.76; p
< 0.001 p < 0.001 0.58 0.23 * 0.32 *
F(2,15) = 35.88; p
< 0.001
p <
0.001
VMA 1.64 1.43 1.41 F(2,15) = 1.64; p =0.226 p = 0.269 1.32 1.27 1.42
F(2,15) = 0.99; p =
0.392 p = 0.307 7.02 6.08 6.03
F(2,15) = 2.67; p =
0.101
p =
0.160
VMA/NE 4.27 14.58 * 5.16 #
F(2,15) = 9.33; p =
0.002 p = 0.002 1.90 4.14
* 2.84 #
F(2,15) = 18.07; p
< 0.001 p < 0.001 12.40
26.82
*
19.67
*#
F(2,15) = 21.03; p
< 0.001
p <
0.001
DA 0.07 0.12 0.07 F(2,15) = 4.31; p =0.033 p = 0.087 0.05 0.09 0.06
F(2,15) =2.35; p =
0.129 p = 0.172 0.15 0.13 0.23
F(2,15) = 3.73; p =
0.048
p =
0.068
DOPAC 0.01 0.02 0.02 F(2,15) = 0.67; p =0.521 p = 0.383 0.01 0.03 0.01
F(2,15) = 3.19; p =
0.069 p = 0.128 0.07 0.07
0.03
*#
F(2,15) = 15.12; p
< 0.001
p =
0.011
DOPAC/DA 0.23 0.17 0.24 F(2,15) = 0.74; p =0.490 p = 0.311 0.06 0.29 0.15
F(2,15) = 2.59; p =
0.107 p = 0.137 0.50 0.57 * 0.12 *
F(2,15) = 23.35; p
<0 .001
p <
0.001
HVA 0.07 0.08 0.08 F(2,15) = 0.06; p =0.941 p = 0.492 0.05 0.09 0.06
F(2,15) = 1.44; p =
0.267 p = 0.263 0.05 0.04 0.16
F(2,15) = 0.71; p =
0.504
p =
0.340
HVA/DA 1.04 0.66 1.06 F(2,15) = 3.78; p =0.046 p = 0.051 1.53 0.88 1.23
F(2,15) = 1.45; p =
0.264 p = 0.227 0.73 0.55 1.51
# F(2,15) = 7.08; p <
0.007 p < 0.01
5-HT 0.68 0.65 0.95 *#
F(2,15) = 8.50; p =
0.003 p = 0.007 1.13 1.12 1.29
F(2,15) = 1.94; p =
0.177 p = 0.172 0.65 0.43 1.01
# F(2,15) = 8.58; p =
0.003
p =
0.011
5HIAA 0.30 0.51 * 0.48 * F(2,15) = 11.55; p< 0.001 p < 0.001 0.64 1.04 * 0.84
F(2,15) = 13.16; p
< 0.001 p < 0.001 0.23 0.26 0.18
F(2,15) = 4.28; p =
0.033
p =
0.077
5HIAA/5-HT4.76 7.36 6.54 F(2,15) = 3.09; p =0.075 p = 0.136 0.57 0.92 * 0.67
# F(2,15) = 13.83; p
< 0.001 p < 0.001 0.38 0.49
0.18
*#
F(2,15) = 18.61; p
< 0.001
p <
0.001
Hippocampus Thalamus
CT DZP CRS ANOVA BS CT DZP CRS ANOVA BS
A
m
in
o
ac
id
s
(n
m
ol
/m
g) ASP 1.77 1.51 2.23 # F(2,15) = 8.59; p =0.003 p = 0.005 2.18 1.80 2.26
# F(2,15) = 6.93; p =
0.007 p = 0.013
GLU 8.42 8.37 9.11 F(2,15) = 0.51; p =0.608 p = 0.382 8.89 8.57 8.22
F(2,15) = 0.35; p =
0.705 p = 0.398
GLN 3.63 4.65 * 4.67 * F(2,15) = 9.94; p <0.001 p = 0.002 4.04 5.37 * 5.06 *
F(2,15) = 17.57; p
< 0.001 p < 0.001
GLY 0.38 0.44 0.44 F(2,15) = 1.00; p =0.388 p = 0.288 0.48 0.50 0.49
F(2,15) = 0.07; p =
0.932 p = 0.932
TAU 5.39 4.98 5.55 F(2,15) = 0.78; p =0.471 p = 0.311 2.36 2.15 2.38
F(2,15) = 1.11; p =
0.354 p = 0.292
GABA 2.00 2.70 * 2.24 F(2,15) = 4.99; p =0.021 p = 0.045 2.55 2.51 2.23
F(2,15) = 1.90; p =
0.182 p = 0.156
One-way ANOVA and Tukey post-hoc test with 10,000 bootstrap (BS) resampling of amino acids and monoamines in the hippocampus, thalamus, and piriform cortex.
Abbreviations: VMA—vanilmandelic acid; NE—norepinephrine; DOPAC—3,4-hydroxyphenylacetic acid; DA—dopamine; 5-HIAA—5-hydroxyindoleacetic acid; HVA—homovanillic
acid; 5-HT—serotonin; ASP—aspartate; GLU—glutamate; GLN—glutamine; GLY—glycine; TAU—taurine; GABA—gamma-aminobutyric acid. * p < 0.05: statistically significant difference
from the CT group; # p < 0.05: statistically significantly difference from the diazepam (DZP) group.
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Figure 2. Effect of SE and CRS treatment on monoamine and amino acid levels in the hippocampus,
thalamus, and piriform cortex. Only compounds for which significant differences were found are
illustrated. * p < 0.05: statistically significant difference. No statistical difference was observed in the
following analyzes: DA turnover, 5-HT turnover, and GLN, GLY, and TAU in the hippocampus; DA
turnover, DA, 5-HT, GLN, GLY, TAU, and GABA on the thalamus; and DA, ASP, GLU, GLN, GLY, TAU,
and GABA in the piriform cortex.
2.2. c-Fos Immunostaining
The c-Fos data was normalized to the volume of each structure (number of c-Fos positive
cells/volume in mm3). Table 2 shows the number of immunopositive cells in the different structures of
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interest and summarizes statistical results. c-Fos expression in all structures analyzed can be found in
Supplementary Figure S5.
In both groups that underwent SE (CRS or DZP) and in all structures analyzed, c-Fos expression
was increased in comparison to CT rats (Supplementary Figure S5), except in the MD where activity
was increased only in the CRS over the CT group (Figure 3A). The comparison between CRS and DZP
groups showed a significantly larger increase in activation in the MD and LD nuclei in CRS treated
rats than in DZP group (Figure 3A,B). Figure 3C shows the c-Fos immunostaining in these areas.
Table 2. Quantification of c-Fos positive cells in CT, DZP and CRS rats.
Structure
Number of Cells
ANOVA Bootstrap
CT DZP CRS
PV 6471 37,435 * 43,927 * F(2,12) = 77.17; p < 0.001 p < 0.001
IL 1275 26,498 * 28,314 * F(2,12) = 119.88; p < 0.001 p < 0.001
ReRh 995 21,466 * 27,867 * F(2,12) = 73.00; p < 0.001 p < 0.001
MD 1571 4517 10,588 *# F(2,12) = 21.85; p < 0.001 p < 0.001
RTN 880 29,169 * 25,824 * F(2,12) = 52.09; p < 0.001 p < 0.001
ZI 1537 11,858 * 13,409 * F(2,12) = 6.08; p = 0.015 p = 0.009
VB 852 4866 * 7562 * F(2,12) = 10.59; p = 0.002 p = 0.003
LD 1291 6698 * 13,880 *# F(2,12) = 33.66; p < 0.001 p < 0.001
GD 2865 234,694 * 208,044 * F(2,12) = 68.35; p < 0.001 p < 0.001
CA3 5832 79,664 * 80,145 * F(2,12) = 48.48; p < 0.001 p < 0.001
CA1 2724 130,109 * 123,864 * F(2,12) = 31.19; p < 0.001 p < 0.001
Pir 3778 213,143 * 203,401 * F(2,12) = 70.09; p < 0.001 p < 0.001
Ent 5117 153,586 * 136,315 * F(2,12) = 47.08; p < 0.001 p < 0.001
Amy 4097 74,388 * 93,834 * F(2,12) = 18.78; p < 0.001 p < 0.001
One-way ANOVA and Tukey post-hoc test with 10,000 bootstrap resampling of the number of c-Fos-positive
cells. Abbreviations: PV—paraventricular thalamic nucleus; IL—intralaminar thalamic nucleus; ReRh—reuniens/
rhomboid thalamic nucleus; MD—mediodorsal thalamic nucleus; RTN—reticular thalamic nucleus; ZI—zona
incerta; VB—ventro-basal thalamic nucleus; LD—laterodorsal thalamic nucleus; DG—dentate gyrus; CA3—Cornu
Ammonis 3; CA1—Cornu Ammonis 1; Pir—piriform cortex; Ent—entorhinal cortex; Amy—amygdala. * p < 0.05:
statistically significant difference from the CT group; # p < 0.05: statistically significant difference from DZP group.
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significant difference from CT rats; # p < 0.05: statistically significant difference from DZP rats.
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The factorial analysis of the data generated two components and revealed a positive correlation
between MD, LD, and ventrobasal (VB) thalamic nuclei, which were negatively correlated with the
dentate gyrus (DG) (Figure 4). This result indicate, for example, that a rat with MD activation has
simultaneously greater activation of the LD and VB nuclei, and little activation of DG.
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(VB), mediodorsal (MD) and laterodorsal (LD) thalamic nuclei, and a negative correlation of these
nuclei with dentate gyrus (DG); (C) Correlation matrix two-by-two illustrating the correlation between
these four structures.
3. Discussion
In the pilocarpine model, CRS is a molecule capable of producing significant changes in the
epileptogenic process. In addition to strong neuroprotection, a subpopulation of rats treated with
CRS developed NCS instead of the convulsive seizures commonly observed in this model [10]. NCS,
the main feature of absence epilepsy, is characterized by the presence of SWDs, accompanied by
behavioral arrest. In rodents these seizures occur at a frequency of 6–10 Hz and are generated within a
thalamo-cortical loop [12,19].
Interestingly, a significan reduction of epileptiform events was observed at 2–3 h fter CRS
administration (i.e., at 4 h after SE onset) in most rats subsequently developing NCS [10]. Therefore,
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our current study looked at neurochemical changes (monoamines and amino acids) and mapped
neuronal activity in regions related to the initiation and generalization of convulsive seizures 4 h after
LiPilo SE onset.
3.1. Neurochemical Changes
As illustrated in Figure 1, CRS may inhibit voltage-gated sodium channels leading to reduced
action potential discharges [13]. CRS also reduces glutamatergic transmission by inhibiting AMPA and
NMDA excitatory post-synaptic potentials [14]. Moreover, this compound acts on DA, NE, and 5-HT
systems [15]. Interestingly, CRS increases the tonic activation of somatodendritic 5-HT1A serotonergic
receptors, thereby enhancing their inhibitory action over pyramidal neurons in the hippocampus [15].
Herein, we assessed the levels of amino acids and monoamines 4 h after SE onset in hippocampus,
piriform cortex and thalamus, when changes in cortical electrical activity are habitually recorded [9].
These three structures were chosen in relation to their importance in the genesis and generalization
of convulsive seizures [18], and the thalamus was studied because of its critical importance in the
occurrence of SWDs [12].
Amino acids: In agreement with previous studies [20], the levels of GABA and GLN were
increased 4 h after the LiPilo SE onset in rats treated with DZP. However, while CRS did not seem to
affect the level of GLN, it normalized the level of GABA in the hippocampus (compared to CT rats).
CRS reduces the glutamatergic transmission by acting on AMPA and NMDA receptors [14], which
may reduce the severity of SE as observed in CRS-treated rats. In addition, the reduction of SE severity
may also be related to the normalization of GABA level in the CRS group.
Monoamines: In hippocampus, thalamus, and piriform cortex of LiPilo SE (DZP rats), there was a
reduction in the NE concentration concomitant with an increase in the utilization rate of NE compared
to the CT group. DA level increased only in the hippocampus of DZP compared to CT rats. These
results are in agreement with previous studies on the hippocampus of rats subjected to pilocarpine
SE [20]. CRS treatment appears to normalize the concentration of monoamines back to control values
(except 5-HT in the hippocampus, which was increased over CT and DZP levels). In the piriform
cortex and thalamus, the NE level was reduced compared to CT rats, and in the piriform cortex only,
5HT and DA turnover were decreased compared to both CT and DZP rats. The effect of CRS on the
monoaminergic system is in agreement with a previous study showing a reduction in the firing rate
of neurons in the ventral tegmental area (VTA–DA neurons), locus coeruleus (LC–NE neurons) and
dorsal raphe nucleus (DRN–5-HT neurons) when CRS was administered over 14 days [15]. Likewise,
the stimulation of 5-HT neurotransmission increases SWDs in animal models of absence epilepsy and
reduces the occurrence of convulsive seizures in genetic epilepsy-prone rats, (GEPRs) [21]. These data
are in line with the present findings.
Therefore, the fact that CRS can act directly on monoaminergic systems [15] and modulate the
level of DA, NE, and 5-HT in the hippocampus, and also in thalamus and piriform cortex (as observed
in the present study), may contribute to its neuroprotective and insult-, disease-modifying effects.
Indeed, these three regions, which have an established role in the epileptic circuitry regarding the
origin and generalization of convulsive seizures, receive monoaminergic projections. Hence, by acting
on the monoaminergic system, CRS may modulate the onset, severity and/or generalization of seizures,
and it clearly emerges from our data that most of the effects of CRS on monoamine levels and turnover
rates appear to normalize the values of saline-treated DZP rats recorded in freely seizing, untreated
rats back to the CT values.
3.2. Cerebral Activity
The epileptic circuitry recruited during convulsive seizures involves temporal structures such
as hippocampus, amygdala, piriform and entorhinal cortices, but also subcortical structures like the
thalamus. These structures have specific roles in the genesis and spread (or generalization) of seizures.
Mapping the activity of structures related to convulsive seizures showed that all temporal regions
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and many thalamic nuclei were significantly more activated in all animals undergoing SE (whatever
the treatment, CRS or DZP) compared to CT rats. No difference was observed in the activity of
temporal structures—the DG, Cornu Ammonis (CA)1, CA3, amygdala (Amy), piriform cortex (Pir),
and entorhinal cortex (Ent)—between the CRS and DZP groups. On the other hand, two thalamic
nuclei (MD and LD) showed stronger activation in rats treated with CRS than in those receiving DZP.
However, it is important to recall that c-Fos labeling reflects regional activation, but does not indicate
whether this activation is excitatory or inhibitory.
Of note, MD and LD thalamic nuclei exert a modulatory role in the control of both convulsive
and non-convulsive seizures, and in epileptogenesis [22–26]. The MD has reciprocal connections with
limbic structures, and the thalamus is associated to physiological activity during SE, providing a
synchronous epileptiform activity between thalamus and hippocampus [22,27]. Interestingly, in rats
with chronic epilepsy, convulsive seizure onset occurs simultaneously in hippocampus and MD,
and the electrical stimulation of the MD induces seizures that generalize faster than those induced
by hippocampal or amygdalar kindling [22,23]. On the other hand, chemical inhibition of the MD
completely blocks convulsive seizures [22,28,29]. However, the seizure-blocking effect of the MD
is site-specific because the blockade of convulsive seizures was obtained only when the chemical
inhibition target was the central portion of the MD, while no effect was observed when the injection
was made in the lateral part of the MD [28].
Besides the role of the MD in the genesis, generalization and modulation of convulsive seizures,
some studies suggest also an important role of the MD in NCS for SWDs. Indeed, in animal models
of absence epilepsy, bilateral lesions of the MD completely abolish SWDs [30]. In contrast, chemical
stimulation of the MD with kainic acid induces SWDs (accompanied by behavioral arrest), which
spread to other thalamic nuclei, cortex and limbic structures [31].
While the MD plays a clear role in epilepsy, the role of the LD is less clear. In the LiPilo model, both
the LD and MD show significantly increased Fluoro-jade B labeling [32], and these nuclei (contrary to
hippocampus and amygdala) present a superoxide mechanism of neuronal injury [33]. In the WAG/Rij
model of absence epilepsy, a higher level of apoptotic cells and a higher expression of caspase-3
were found in the LD [34]. It is interesting to note that CRS treatment produces dose-dependent
neuroprotection of the LD and MD [10]. Furthermore, our results indicate that the activity of the LD
and MD are positively correlated with the activity of the VB. The VB thalamic complex is an essential
component of the thalamocortical loop generating SWDs [12,35].
Therefore, by stimulating the MD, both convulsive and absence-like seizures can be induced,
while the inhibition or lesion of this nucleus blocks both seizure types. The increased activity in the MD
of rats treated with CRS suggest that this thalamic nucleus may be a key structure, together with the
LD and VB, in the epileptogenesis-modifying effect of CRS and in the expression of different seizures
types observed in the current study.
4. Materials and Methods
4.1. General Procedure
Animals: Thirty-four adult male Sprague–Dawley rats (350 ± 30 g) provided by the University of
São Paulo were housed under controlled conditions (22 ± 1 ◦C, 12 h/12 h light/dark cycle, lights on at
7:00 a.m.) with water and food ad libitum. The ethics research committee of the Federal University
of São Paulo (CEP N◦ 2072/11) approved all experiments. Efforts were made to minimize pain or
discomfort of animals. The experiments were performed following the principles outlined in the
Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines and the Basel declaration
(http://www.basel-declaration.org). The Replacement, Refinement and Reduction of Animals in
research (3R) concept has been considered when planning the experiments.
SE induction: Rats were injected i.p. with 127 mg/kg lithium chloride. About 18 h later they
received methylscopolamine (1 mg/kg s.c., Sigma-Aldrich, Saint Louis, MO, USA) in order to limit the
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undesirable peripheral effects of pilocarpine. SE was induced 30 min later by the administration of
pilocarpine (25 mg/kg s.c., Sigma-Aldrich). The control group received lithium chloride and saline
instead of pilocarpine.
Carisbamate treatment: One hour after SE onset, rats were randomly administered with diazepam
(DZP, 2.5 mg/kg i.m., Roche, Meylan, France) or CRS (90 mg/kg i.p., Johnson & Johnson Research
& Development, L.L.C., Raritan, NJ, USA) dissolved in 45% hydroxypropyl-β-cyclodextrin (Acros
Organics, Geel, Belgium). DZP administered at low doses enhanced survival of rats without modifying
SE characteristics, as reported in [36] and our own experience. The untreated group received saline
instead of CRS. Rats were euthanized 4 h after SE onset. The LiPilo-DZP group represents our reference
group for the study of SE only. DZP was used in this short-term experiment because it is the standard
treatment of all the animals studied in the long-term.
Experimental groups: Three experimental groups were used: (1) CT—a control group receiving
lithium chloride and saline; (2) DZP—rats that underwent SE and were treated with DZP 1 h after SE
onset; and (3) CRS—rats that underwent SE and were treated with CRS 1 h after SE onset.
4.2. Measurement of Amino Acid and Monoamine Concentrations
Sample preparation and HPLC assay: Eighteen animals we used in this experiment (n = 6/group).
Four hours after SE onset animals destined to amino acid and monoamine quantification by HPLC
were killed by decapitation and the hippocampus, piriform cortex, and thalamus were dissected out,
weighed and stored at −80 ◦C. The amino acids aspartate (ASP), glutamate (GLU), glutamine (GLN),
glycine (GLY), taurine (TAU) and gamma-aminobutyric acid (GABA), and the monoamines dopamine
(DA), norepinephrine (NE) and serotonin (5-HT) as well as their respective metabolites (DOPAC, HVA,
and 5-HIAA) were quantified. The sample preparation protocol was previously described [20].
4.3. c-Fos Immunolabelling
Histology: Fifteen animals were used for c-Fos expression determinations (5/group). Four hours
after SE all rats were deeply anesthetized with a solution of ketamine (80 mg/kg, i.p.)/xylazine
(30 mg/kg, i.p.) and transcardially perfused with saline (0.9%) followed by phosphate-buffered 4%
formaldehyde. After perfusion, animals were decapitated and brains were kept “in situ”, immersed
in the fixative solution for 20 h, removed from the skull, and post-fixed overnight. The brains were
sectioned in free-floating coronal slices, 40 µm thick, using a vibratome. Sections were stored in
wells containing cryoprotectant at −20 ◦C. One of the 10 sets of sections between Bregma +3.72 mm
and −6.84 mm was used for c-Fos immunolabeling. The sections were incubated with the primary
polyclonal anti-c-Fos antibody. After washing, the sections were incubated with the biotinylated
secondary antibody. The positive staining was visualized with a solution of 3,3′-diaminobenzidine.
The sections were separated and mounted on slides. The specificity of the antibody was tested by
incubation without the primary antibody while all other procedures were identical.
Regions of interest delineation: The regions of interest (ROI) were hippocampal subregions
(DG, CA1, and CA3), the basolateral amygdaloid nucleus (Amy), the piriform cortex (Pir),
the entorhinal cortex (Ent) and thalamic nuclei: paraventricular (PV), ventrobasal (VB), zona incerta
(ZI), intermediolateral (IM), thalamic reticular nucleus (TRN), reuniens/rhomboid (ReRh), mediodorsal
(MD), and laterodorsal (LD). All regions of interest were delineated based on the Paxinos and Watson
rat brain atlas [37]. Supplementary Figure 1 shows the delineation of ROIs.
Stereological design: Estimation of c-Fos positive cells and the volume of regions of interest
was obtained using the Cavalieri’s method combined with systematic random sampling [38]. The
precision of estimation is described by the coefficient of error. Estimations were performed using the
Mercator software and a microscope (Leica DM5500B). Slides were analyzed using a 2.5 X objective.
Digital live microscope images were visualized by a high-resolution Microfire by an Optronic camera.
For hippocampus, amygdala, piriform and entorhinal cortices, we used a 30 × 30 µm dissector spaced
100 × 100 µm, and for thalamic nuclei we used a 40 × 40 µm dissector spaced 60 × 60 µm.
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Statistical analysis: For c-Fos labeling and neurochemical quantification we used a one-way
analysis of variance (ANOVA). The post-hoc Tukey test was used when appropriate to identify
statistical significance. Both ANOVA and post-hoc Tukey were performed with 10,000 bootstrap
resampling. A factorial analysis was used to assess the correlation between the activities of the
different structures of interest labeled with c-Fos. Statistical analysis was performed in R version
3.0.2 [39].
5. Conclusions
Herein, we observed that CRS may affect neuronal excitability during SE. CRS plays a modulatory
role on the monoaminergic system, most often preventing the SE-induced changes recorded in DZP
rats and potentially minimizing its effect on the genesis and generalization of convulsive seizures.
In addition, CRS appears to normalize the concentration of GABA. However, in terms of cellular
activity, only the activity of thalamic MD and LD were significantly different in rats treated with
CRS compared to animals treated with DZP. Together with literature data, our results suggest that
the thalamic MD may be a key region in the modulation of epileptogenesis by CRS, minimizing the
changes in that structure, and hence allowing the expression of SWDs instead of convulsive seizures.
This hypothesis would need in vivo electrophysiological recording experiments for confirmation.
Figure 5 summarizes the connectivity between structures related to convulsive seizures and includes
our results in a general functional scheme.
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Figure 5. Schematic representation of the acute changes in the hippocampus, piriform cortex,
and thalamus based on c-Fos and HPLC-measured changes. Entorhinal cortex (Ent) is the main entrance
of hippocampus projecting directly into DG and CA3 via the perforant pathway (a), but projects also to
CA1 and the subiculum (Sub). Mossy fib s proje from DG to CA3 (b) and the Schaffer collaterals
connect CA3 to CA1 (c). CA1 sends efferent projections to the subiculum and the entorhinal cortex.
The subiculum sends also efferent projections into entorhinal cortex. The piriform cortex sends
projections to the subiculum, entorhinal cortex, amygdala and MD thalamic nucleus, and receives
efferent projections coming from the thalamic reuniens nucleus. Finally, the MD als receives afferences
coming from ntorhinal c rtex, amygdala, and motor cortex. Midline thalamic nucl i (MD, Re and
Rh) and the LD nucleus send projections to the hippocampal formation. At the bottom of the figure,
the comparisons indicated are as follows: increase and decrease occurring in CRS-treated rats compared
to CT. Normaliz tion means values ide tic l in CRS and CT r ts and ost ften represent decreases
that occur in CRS compared to DZP rats.
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